@cnbc: M42 CEO Dimitris Moulavasilis says patients own their genomic data — and that a genome should not become a commercial asset. ⠀ In an interview with CNBC’s Dan Murphy, Moulavasilis said M42 acts as a custodian of genomic data and that patients must consent before it is used for their care or for clinical research. ⠀ “My view is it should not,” he said, when asked whether a genome should ever become a commercial asset. ⠀ Watch the full interview on "Managing Middle East with Dan Murphy" by tapping the #linkinbio.

cnbc

Open In TikTok:

Region: US

Sunday 18 October 2026 09:00:09 GMT